Immune Checkpoint Inhibitor-Mediated Endocrinopathies: A Consensus Statement

American Association of Clinical Endocrinology Disease State Clinical Review - Evaluation and Management of Immune Checkpoint Inhibitor-Mediated Endocrinopathies: A Practical Case-Based Clinical Approach

Kevin C. J. Yuen, MD, FRCP, FACE, Susan L. Samson, MD, PhD, FRCPC, FACE, Irina Bancos, MD, Aidar R. Gosmanov, MD, PhD, FACE, Sina Jasim, MD, MPH, Leslie A. Fecher, MD, Jeffrey S. Weber, MD, PhD

In recent years, with increasing numbers of patients with cancer being treated with ICIs, more clinicians in a variety of specialties are called upon to diagnose and treat ICI-mediated endocrinopathies. Herein, we review case scenarios of various clinical manifestations, and emphasize the need for a high index of clinical suspicion by all clinicians caring for these patients including endocrinologists, oncologists, primary care providers, and emergency department physicians. We also provide diagnostic and therapeutic approaches for ICI-induced endocrinopathies, and we propose that patients on ICI therapy be evaluated and treated by a multidisciplinary team in collaboration with endocrinologists.

The purpose of this case-based clinical review is to provide a practical approach for clinicians regarding the management of patients with immune checkpoint inhibitor (ICI)-mediated endocrinopathies.

Read the white paper to learn how to:

  • Summarize the use of ICI (anti-CTLA-4, anti-PD1, and anti-PD-L1) therapies
  • Review the clinical presentation of ICI-related endocrinopathies
  • Discuss the diagnosis and management approaches to endocrinopathies related to ICI therapy
  • Highlight the role of the endocrinology team in the multidisciplinary management of ICI-induced endocrinopathies

Published in Endocrine Practice, Volume 28, Issue 7, July 2022